DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Synthetic lethality
Synthetic lethality
DNA Repair and Synthetic Lethality
The Tumor Therapy Landscape of Synthetic Lethality
Mutational Signatures Are Markers of Drug Sensitivity of Cancer Cells
Approaches to Identifying Synthetic Lethal Interactions in Cancer
RAD51C-Deficient Cancer Cells Are Highly Sensitive to the PARP Inhibitor Olaparib
Synthetic Lethal Screening in the Mammalian Central Nervous System Identifies Gpx6 As a Modulator of Huntington’S Disease
Prognosis, Biology, and Targeting of TP53 Dysregulation in Multiple Myeloma
Loss-Of-Function Genetic Screens As a Tool to Improve the Diagnosis and Treatment of Cancer
PALB2 Mutations and Breast-Cancer Risk Michele K
Synthetic Lethality of a Cell-Penetrating Anti-RAD51 Antibody in PTEN-Deficient Melanoma and Glioma Cells
Genetic Screening Approaches to Cancer Driver Characterization and Synthetic Lethal Target Discovery
ATM-Deficient Cancers Provide New Opportunities for Precision Oncology
A Synthetic Lethal Screen Identifies ATR-Inhibition As a Novel Therapeutic Approach for POLD1 -Deficient Cancers
Evolution of Cancer Genomics and Its Clinical Implications
Oncogeneticsoncogenetics Clinical Genetics
ATM Mutations in Cancer: Therapeutic Implications Michael Choi, Thomas Kipps, and Razelle Kurzrock
Synergistic Targeting and Resistance to PARP Inhibition in DNA Damage
Elaborating the Mechanism of PARP Synthetic Lethality Following ATM
Top View
Regulation of DNA Damage Response and Homologous Recombination Repair by Microrna in Human Cells Exposed to Ionizing Radiation
CRISPR Screens in Synthetic Lethality and Combinatorial Therapies for Cancer
Drug Driven Synthetic Lethality: Bypassing Tumor Cell Genetics with a Combination of Dbait and PARP Inhibitors
RAD51-Mediated DNA Homologous Recombination Is Independent of PTEN Mutational Status
Synthetic Lethality-Mediated Precision Oncology Via the Tumor Transcriptome
Synthetic Lethality: Beating Cancer at Its Own Game Jane De Lartigue, Phd
ATM and ATR As Therapeutic Targets in Cancer
Breast Cancer Predisposition Genes and Synthetic Lethality
Exploiting Synthetic Lethal Vulnerabilities for Cancer Therapy
Compound F779-0434 Causes Synthetic Lethality in BRCA2-Deficient Cancer Cells by Disrupting RAD52– Cite This: RSC Adv.,2018,8, 18859 Ssdna Association†
CIP2A Is a Prime Synthetic-Lethal Target for BRCA-Mutated Cancers
Mir-509-3 Augments the Synthetic Lethality of Parpi by Regulating HR
ATM Loss Leads to Synthetic Lethality in BRCA1 BRCT Mutant Mice Associated with Exacerbated Defects in Homology-Directed Repair
Epigenetic Synthetic Lethality Approaches in Cancer Therapy Haoshen Yang, Wei Cui* and Lihui Wang*
ATM Signalling and Cancer
What's Next After PARP Inhibitors for BRCA Mutated Cancers?
Synthetic Lethality As an Engine for Cancer Drug Target Discovery
Inhibition of DNA Repair in Cancer Therapy: Toward a Multi-Target Approach
The Therapeutic Significance of Mutational Signatures from DNA
Conceptual Frameworks of Synthetic Lethality in Clear Cell Carcinoma of the Ovary (Review)
Trajectory and Uniqueness of Mutational Signatures in Yeast Mutators
Targeting Topoisomerase I in the Era of Precision Medicine
Comprehensive Analysis of DNA Damage Repair Genes Reveals
Synthetic Lethality Screenings for Drug Discovery